SUBSCRIBE
SUBSCRIBE
News   Drug Development

Amgen (JOBS) Trial Finds No Heart Benefit with Aranesp

August 26, 2009 | 
1 min read

Bookmark and Share

Reuters -- A trial of Amgen Inc’s Aranesp found the blockbuster anemia drug does not have a significant effect on the risk of heart attack and other cardiac events in kidney patients, the company said on Tuesday.

Clinical research Phase III Postmarket research
Amgen
MORE ON THIS TOPIC
Business consultant. Hands help a businessman is falling from a graph vector
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
March 3, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Glitter Vibrant Spheres Abstract Background Digital Renderingv
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
March 3, 2025
 · 
2 min read
 · 
Annalee Armstrong
Pop art Medicine pill or tablet icon isolated on color background. Capsule pill and drug sign. Pharmacy design. Vector Illustration
Pain
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
March 3, 2025
 · 
2 min read
 · 
Dan Samorodnitsky